EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms.
about
Mechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate CancerDNA-PK: a dynamic enzyme in a versatile DSB repair pathwayFound in translation: Integrating laboratory and clinical oncology researchEpidermal growth factor receptor inhibitors for radiotherapy: biological rationale and preclinical results.Mechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf>MEK>ERK mitogen-activated protein kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition of MEKPromising outcomes of definitive chemoradiation and cetuximab for patients with esophageal squamous cell carcinomaBiologic therapy in esophageal and gastric malignancies: current therapies and future directionsThe emerging role of nimotuzumab in the treatment of non-small cell lung cancer.Effect of combined irradiation and EGFR/Erb-B inhibition with BIBW 2992 on proliferation and tumour cure in cell lines and xenografts.The Molecular Crosstalk between the MET Receptor Tyrosine Kinase and the DNA Damage Response-Biological and Clinical AspectsImpact of oncogenic K-RAS on YB-1 phosphorylation induced by ionizing radiation.Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung CancerAstrocytes reverted to a neural progenitor-like state with transforming growth factor alpha are sensitized to cancerous transformation.Radiotherapy and erlotinib combined: review of the preclinical and clinical evidenceThe current state of targeted agents in rectal cancer.Modelling the correlation between EGFr expression and tumour cell radiosensitivity, and combined treatments of radiation and monoclonal antibody EGFr inhibitors.Nimotuzumab promotes radiosensitivity of EGFR-overexpression esophageal squamous cell carcinoma cells by upregulating IGFBP-3.Erlotinib resistance in lung cancer: current progress and future perspectives.Breast cancer subtypes: response to radiotherapy and potential radiosensitisation.Biologically targeted therapeutics in pediatric brain tumors.Cell adhesion-mediated radioresistance revisited.The status of targeted agents in the setting of neoadjuvant radiation therapy in locally advanced rectal cancers.Radiation-induced EGFR-signaling and control of DNA-damage repair.Erlotinib and concurrent chemoradiation in pretreated NSCLC patients: radiobiological basis and clinical resultsCombining radiotherapy with MEK1/2, STAT5 or STAT6 inhibition reduces survival of head and neck cancer lines.Receptor signaling as a regulatory mechanism of DNA repair.Radiosensitizers in pancreatic cancer--preclinical and clinical exploits with molecularly targeted agents.Radiosensitising agents for the radiotherapy of cancer: novel molecularly targeted approaches.Milestones in normal tissue radiation biology over the past 50 years: from clonogenic cell survival to cytokine networks and back to stem cell recovery.Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity.Carbon ion irradiation withstands cancer stem cells' migration/invasion process in Head and Neck Squamous Cell Carcinoma (HNSCC).Heterogeneity of tumour response to combined radiotherapy and EGFR inhibitors: differences between antibodies and TK inhibitors.Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and TherapyCetuximab and chemoradiation for rectal cancer--is the water getting muddy?Role of cell cycle perturbations in the combination therapy of chemotherapeutic agents and radiation.Combination of radiotherapy and targeted therapies in the treatment of locally advanced non-small cell lung cancer.Differential proteomics in the search for biomarkers of radiotherapy resistance.Basic mechanisms of therapeutic resistance to radiation and chemotherapy in lung cancer.Erlotinib: early clinical development in brain cancer.Opportunities and challenges of radiotherapy for treating cancer.
P2860
Q26766638-B2253DA4-4279-43D8-8B37-7866922953E8Q26866928-C006BA11-E78E-4860-98B8-9427575C1B9EQ28744471-29904E1F-ABCB-446B-9F03-34FECCA303E3Q33353609-4F0C6EEB-1478-4FBC-9F82-E08050BDBDBFQ33562476-0542F62D-DA6A-4948-B0F8-71D226AA199CQ33711287-D19C7067-54BE-453F-82B1-492DF8527B7DQ33895597-DED0A3D7-C8F1-4E5C-8BC5-DD184CD01CBFQ34343043-8534586F-AF22-4837-A398-F7BE666CE67EQ34740289-226DE9EC-C6E1-4502-B094-57428E510D4FQ35078950-219C3EF2-223E-492E-AD86-829B5BA2C573Q35558949-84086ED9-DBB0-4730-848E-0D93BF95078BQ35608002-B535D359-D708-4EA4-8A51-CAE07FBB1786Q35631417-5EC242D3-F51E-4879-8153-4F56D311EBF4Q35970960-5614F472-BBDA-49C3-9027-B6D0F11FAD9BQ35996651-458F80FF-84CC-4CC6-A2FD-F26E51B52ABAQ36412543-9DE1D795-9067-418B-A75B-498C750A612FQ36517741-8CACA348-3642-4095-B325-A86A8FF87AA4Q36605522-903EC846-5F02-4A8F-9747-F6138AE3AEC6Q36715983-F463ACC4-CE0D-411C-84D8-2C1481ADE9F2Q36844744-3D943944-B200-47CE-9936-A0AB02CDCA8FQ36977842-866191D5-96B7-435D-A992-6F921B780142Q37015715-914C9E36-F28B-44FD-BFE8-4E34C9A517D8Q37024025-E4F9B374-BA41-4C34-905C-38E5CDAC3CC5Q37105715-065414AD-73EA-4198-BC33-40882435B28EQ37347999-BCD5736A-DB9F-4F27-AD57-646E84794834Q37368256-BFC6011F-EBE7-4D1B-A707-06E15B5D0901Q37403232-8FE9B0C1-8D89-4679-94D0-224B4973DEE4Q37489947-4DEC97DF-164B-446D-8A9B-1BDA62D52F99Q37532183-3C739374-E002-42B4-BD19-242E82566FEBQ37558534-FD776143-1AD9-45B5-965C-0EE3BF6E2C33Q37565255-8470DF1C-876D-40A7-B74E-8BF133648E03Q37628728-53BD9088-B7C4-4486-B804-B325DD2E98EEQ37689802-2E3A5EEC-B849-433D-AFE8-4930BC79A81FQ37697800-597721CB-D73D-4435-BFB1-F43AF6DD9480Q37797479-12C80CAE-F8F5-4C64-BCBC-C14A484DE536Q37853481-F04A2C80-4C41-4EBB-A7A4-67D7E61E5438Q37912208-4B16B4D6-6F4D-4F55-BE9F-86BAFA5EC134Q38109469-2C988BA2-C85B-40D0-9756-66208BED94D0Q38212394-AF46B30E-73F5-47EB-83E6-19C5771332F8Q38539957-1D5343E3-5BDA-4E8D-B306-5A25228F8279
P2860
EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms.
@en
type
label
EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms.
@en
prefLabel
EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms.
@en
P2093
P1476
EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms.
@en
P2093
Ekkehard Dikomey
H Peter Rodemann
Klaus Dittmann
Ulla Kasten-Pisula
Wolfgang Dörr
P304
P356
10.1016/J.RADONC.2007.04.006
P577
2007-05-14T00:00:00Z